Grassi W, Montecucco C
Clinica Reumatologica, Università Politecnica delle Marche, Ancona, Italia.
Reumatismo. 2005;57(4 Suppl):30-3. doi: 10.4081/reumatismo.2005.4s.30.
The article describes the EMEA approved indications of TNFα antagonists (adalimumab, etanercept and infliximab) in the various clinical conditions and their increasing use in diseases other than those already approved. The Authors discuss their use during pregnancy, the efficacy of a second TNFα antagonist after failure or side effects development with a previous biologic agent and the different efficacy of the various agents depending on the different clinical conditions.
本文描述了欧洲药品管理局（EMEA）批准的肿瘤坏死因子α（TNFα）拮抗剂（阿达木单抗、依那西普和英夫利昔单抗）在各种临床情况下的适应症，以及它们在已批准疾病以外的其他疾病中的使用日益增加的情况。作者讨论了它们在孕期的使用、在先前生物制剂治疗失败或出现副作用后使用第二种TNFα拮抗剂的疗效，以及不同药物在不同临床情况下的不同疗效。
